Aerovate Therapeutics, INC Schedule 13D activist filings
Filed when an investor crosses five percent and intends to influence the company — the activist disclosure.
Fairmount Funds Management LLC reports a 19.99% beneficial ownership stake in Jade Biosciences following a lock-up agreement.
Sofinnova Venture Partners X and its affiliates now hold less than 5% of Jade Biosciences' common stock following a merger and reverse stock split.
Fairmount Funds Management and its affiliates increased their beneficial ownership in Jade Biosciences, Inc. to 19.99% through a recent $20 million private placement.
SCHEDULE 13D: Fairmount Funds Management Discloses Significant 19.99% Stake in Newly Merged Jade Biosciences, Inc.
Fairmount Funds Management LLC and its affiliates have disclosed a 19.99% beneficial ownership stake in Jade Biosciences, Inc. following a recent merger and corporate restructuring.
SCHEDULE 13D/A: RA Capital Management Reduces Stake in Jade Biosciences Following Merger and Reverse Stock Split
RA Capital Management and its affiliates have reduced their beneficial ownership in Jade Biosciences, Inc. to below 5% following a corporate merger and reverse stock split.
SCHEDULE 13D/A: Atlas Venture Reports Diluted Stake in Jade Biosciences Following Aerovate Merger and Reverse Stock Split
Atlas Venture entities have reported a significant reduction in their beneficial ownership of Jade Biosciences, Inc. common stock, falling below the 5% threshold, following the completion of Jade Biosciences' merger with Aerovate and a subsequent 1-for-35 reverse stock split.